Vistagen Reports First Patient Dosing in P-I Study of PH10 to Treat Major Depressive Disorder


The first cohort has been dosed in P-I study evaluating the safety and tolerability of PH10 in patients (n=12) with MDD in the US. The study completion is expected by Q1’23 with top-line results before the H1’23
The study is conducted to determine the safety profile equivalent to three previous clinical studies in Mexico incl. a published P-IIa study, as well as to execute development plans for a P-IIb study as a stand-alone treatment for MDD
PH10, a pherine nasal spray with potential rapid-onset MOA. It binds to receptors of chemosensory neurons in the nasal passages and increases the activity of the limbic-hypothalamic sympathetic nervous system and thus increasing the release of catecholamines

Ref: Businesswire | Image: Vistagen

Related News:- VistaGen Therapeutics Reports Positive Results of PH94B in P-III study for Social Anxiety Disorder (SAD)